Study supports pricing long-acting injectable cabotegravir to compete with generic oral HIV PrEP
Effective oral PrEP limits the additional price payers should be willing to pay for long-acting injectable PrEP, say researchers.
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
Departments, Centers, & Programs:
Clinical Interests:
Treats:
Languages:
Mass General Infectious Diseases
55 Fruit St.
Boston, MA 02114
Phone: 617-726-3906
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is the #1 Research Hospital in America and recognized in 14 specialties assessed by U.S. News & World Report.
Effective oral PrEP limits the additional price payers should be willing to pay for long-acting injectable PrEP, say researchers.
New research suggests when the COVID-19 pandemic is slowing, low-cost, recurring screening of asymptomatic people – at an expense of approximately $3 or less per test every two weeks – could decrease COVID-19 infections and deaths and be cost-effective.
Screening every three months compared to current recommendations of annual screening would improve clinical outcomes and be cost-effective.